Volatility remains within normal ranges, which is generally favorable for maintaining avgr stock forecast stability without sharp downside shocks. Avinger Inc ( NASDAQ:AVGR ) is set to release its Q3 2024 earnings on Nov 7, 2024. The consensus estimate for Q3 2024 revenue is $1.64 million, and the earnings are expected to come in at -$2.03 per share. The full year 2024's revenue is expected to be $7.2 million and the earnings are expected to be -$4.69 per share. More detailed estimate data can be found on the Forecast page . On July 6th, Avinger, Inc. (NASDAQ: AVGR) has submitted a 510(k) application to the FDA for a new Pantheris clinical indication for in-stent restenosis (ISR) therapy in lower extremity arteries. If approved, the Pantheris atherectomy device will allow physicians to see from the inside of the artery during an atherectomy procedure using optical coherence tomography imaging. Shares of Avinger, Inc. (NASDAQ: AVGR) jumped 3.6% at $1.15 intra-day and increased 9% after the announcement. The latest avgr stock forecast indicates moderate upside potential, with analysts setting a 12-month target range between $2.80 and $3.